Alpha‐actinin‐4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas

MLA

Jitsuo Usuda, et al. “Alpha‐actinin‐4 (ACTN4) Gene Amplification Is a Predictive Biomarker for Adjuvant Chemotherapy with Tegafur/Uracil in Stage I Lung Adenocarcinomas.” Cancer Science, vol. 113, Jan. 2022, pp. 1002–09. EBSCOhost, https://doi.org/10.1111/cas.15228.

APA

Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, & Norihiko Ikeda. (2022). Alpha‐actinin‐4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas. Cancer Science, 113, 1002–1009. https://doi.org/10.1111/cas.15228

Chicago

Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, et al. 2022. “Alpha‐actinin‐4 (ACTN4) Gene Amplification Is a Predictive Biomarker for Adjuvant Chemotherapy with Tegafur/Uracil in Stage I Lung Adenocarcinomas.” Cancer Science 113 (January): 1002–9. doi:10.1111/cas.15228.